Literature DB >> 14748663

Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.

Paul Gagne1, Abebe Akalu, Peter C Brooks.   

Abstract

It is well known that angiogenesis plays an important role in malignant tumor progression. Thus, a great deal of effort has been focused on the development and evaluation of novel angiogenesis inhibitors for the treatment of human malignancies. In this review, the role of angiogenesis in tumor growth will be examined, as well as efforts to develop and use antiangiogenic therapies to treat malignant tumors. In particular, focus will be on the extracellular environment and the challenges of using antiangiogenic therapy in the clinical setting, in terms of toxicities, potential mechanisms of tumor resistance and optimization of clinical trial design. Attention will be focused upon a mechanistic understanding of the variability and dynamic nature of individual tumor microenvironments, and the potential impact this has on antiangiogenic therapies. Copyright Future Drugs Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748663     DOI: 10.1586/14737140.4.1.129

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  4 in total

1.  Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo.

Authors:  Jennifer M Roth; Abebe Akalu; Anat Zelmanovich; Desiree Policarpio; Bruce Ng; Shannon MacDonald; Silvia Formenti; Leonard Liebes; Peter C Brooks
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 2.  Integrins as "functional hubs" in the regulation of pathological angiogenesis.

Authors:  Liangru Contois; Abebe Akalu; Peter C Brooks
Journal:  Semin Cancer Biol       Date:  2009-05-29       Impact factor: 15.707

3.  Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis.

Authors:  Amy L Bauer; Trachette L Jackson; Yi Jiang
Journal:  PLoS Comput Biol       Date:  2009-07-24       Impact factor: 4.475

4.  Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.

Authors:  Adilson Kleber Ferreira; Vanessa Morais Freitas; Débora Levy; Jorge Luiz Mária Ruiz; Sergio Paulo Bydlowski; Rose Eli Grassi Rici; Otaviano Mendonça R Filho; Gilberto Orivaldo Chierice; Durvanei Augusto Maria
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.